Loading...

MNKD MANNKIND CORP Product Launches 8-K Filing

MNNK

MNKD

MANNKIND CORP

(MNKD)

2025 8-K

Earnings Report

MannKind Announcement

Filing Amendment

Trial Discontinuation

Financial Update

MannKind Acquisition

Collaboration Expansion

Merger Agreement Signed

Financial Statements

Financial Statements

Financial Results

Management Change

Equity Exchange

Financial Results

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

CFO Retirement and Appointment

Earnings Reports

Agreement with Sagard Healt...

Supply Agreement Amendment

Earnings Reports

Earnings Reports

Annual Meeting Approval

Earnings Reports

External Links:

MannKind Corporation announced on November 10, 2025, that it is discontinuing its Phase 3 clinical trial for MNKD-101 due to no participants showing evidence of sputum culture conversion. This decision follows a review by the data safety monitoring board on November 8, 2025, which found the trial unlikely to meet its primary endpoint.

AI Assistant

MANNKIND CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.